Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Season 14 Episode 17  ·  Sep 16, 2025, 04:22 PM
Headliner
Share
Subscribe
In this podcast, experts Aditya Bardia, MD, MPH, FASCO, Erika P. Hamilton, MD, and Virginia Kaklamani, MD, DSc, discuss frequently asked questions regarding the use of antibody-drug conjugates (ADCs) in triple-negative breast cancer (TNBC).
Share
Subscribe
Next
Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air